Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

228.25 -0.43 (-0.19%)
Official Closing Price Updated: 7:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
88 89 Next >
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
--News Direct-- 
Via News Direct
AbbVie's Options Frenzy: What You Need to Know
 
Via Benzinga
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Wednesday Morning
Via Investor Brand Network
$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug... 
Via TheNewswire.com
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
AbbVie Inc Chart Analysis
Technical analysis of the stock chart for ABBV. 
Via Talk Markets
2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now
All three of these stocks offer attractive dividend yields, but one looks risky. 
Via The Motley Fool
ABBV: This Top Biotech Just Went On A Buying Spree
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). 
Via Talk Markets
2 No-Brainer Dividend Stocks to Buy for the New Year
These companies have fantastic track records of maintaining and raising their payouts. 
Via The Motley Fool
3 Dividend Stars Every Investor Should Own to Survive a Market Crash
Prepare for the worst but hope for the best by buying dividend stocks for a market crash that can provide both growth and income. 
Via InvestorPlace
AbbVie Stock Moves With Rising Relative Strength, Still Room To Grow
AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
Breaking Down AbbVie: 7 Analysts Share Their Views
 
Via Benzinga
AbbVie's Options Frenzy: What You Need to Know
 
Via Benzinga
2 Genius Safe Stocks to Buy for 2024 and Beyond
These companies have considerable profits and tried-and-true dividends in common. 
Via The Motley Fool
7 Dividend Aristocrats That Will Pay You for Years to Come
If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024. 
Via InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
These stocks may help you win in 2024 -- no matter what the market does. 
Via The Motley Fool
S&P 500 Shatters Records: The Top-Performing Stocks In January 2024
2023 was a historical milestone for S&P 500 as it once again surpassed record highs, largely due to tech giants and artificial intelligence. Top gainers were NVIDIA, Meta Platforms, and AMD. 
Via Benzinga
Topics Artificial Intelligence Stocks
Pfizer, Autodesk, AbbVie And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named Health Care Select Sector SPDR Fund (NYSE: XLV) 
Via Benzinga
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. 
Via Benzinga
2 Beaten-Down Stocks to Buy Hand Over Fist This Year
Don't give up on these stocks too soon. 
Via The Motley Fool
Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation. 
Via Benzinga
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named Crown Castle Inc. 
Via Benzinga
Better Growth Stock: Abbott vs. AbbVie
These healthcare giants also offer investors the promise of increasing passive income. 
Via The Motley Fool
Here's the Average Amount Investors Have in Stocks by Age 40 and Which Stocks I Recommend Today
Curious as to how your portfolio stacks up? Take a look. 
Via The Motley Fool
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.